Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates
06:26pm, Thursday, 17'th Feb 2022
Exelixis (EXEL) delivered earnings and revenue surprises of 314.29% and 26.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Exelixis Q4 2021 Earnings Preview (NASDAQ:EXEL)
10:35pm, Wednesday, 16'th Feb 2022 Seeking Alpha
Exelixis (NASDAQ:EXEL) is scheduled to announce Q4 earnings results on Thursday, February 17th, after market close.The consensus EPS Estimate is $0.16 (+14.3% Y/Y) and the consensus…
Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More
02:11pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.
Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial
02:14pm, Tuesday, 15'th Feb 2022 Benzinga
Bristol Myers Squibb Co (NYSE: BMY ) and Exelixis Inc (NASDAQ: EXEL ) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo (nivolumab) and Cabometyx (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma. The updated results will be featured at the American Society of Clinical Oncology (ASCO) 2022 Genitourinary Cancers Symposium. With a median follow-up of 32.9 months, … Full story available on Benzinga.com
Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial
09:14am, Tuesday, 15'th Feb 2022
Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo (nivolumab) and Cabometyx (cabozantinib) v
Exelixis: Rangebound Forever
08:04am, Monday, 14'th Feb 2022
Exelixis stock remains stagnant despite strong revenue.
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
08:01pm, Thursday, 10'th Feb 2022 Zacks Investment Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
04:08pm, Thursday, 10'th Feb 2022
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Did Hedge Funds’ Exelixis, Inc. (EXEL) Bets Fare?
08:28pm, Monday, 07'th Feb 2022 Insider Monkey
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
03:00pm, Monday, 07'th Feb 2022 Zacks Investment Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
2 Biotech Stocks That Could Make You Richer
04:15pm, Wednesday, 02'nd Feb 2022 The Motley Fool
These two companies are down, but they aren't yet out.
2 Biotech Stocks That Could Make You Richer
11:15am, Wednesday, 02'nd Feb 2022
These two companies are down, but they aren't yet out.
Exelixis (EXEL) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference
07:25pm, Monday, 24'th Jan 2022 Seeking Alpha
5 Value Stocks That Can Make You Richer in 2022
10:06am, Thursday, 20'th Jan 2022 The Motley Fool
These time-tested companies are deeply discounted and begging to be bought.
3 Biotech Stocks Wall Street Thinks Could Soar 50% or More in 2022
12:01pm, Friday, 14'th Jan 2022 The Motley Fool
The analysts might be overly optimistic in some cases, though.
